Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

THOUSAND OAKS, Calif., Sept. 20, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the Phase 3 GLAGOV (GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy as Measured by IntraVascular Ultrasound) trial evaluating the effect of Repatha® (evolocumab) on… http://www.prnewswire.com/news-releases/amgen-announces-positive-top-line-results-from-phase-3-glagov-imaging-study-of-repatha-evolocumab-300330644.html